Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years)

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 10, 2015, Pages 2337-2344

  Guo, Fangjian ^a   Hirth, Jacqueline M ^a   Berenson, Abbey B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

High risk type; HPV vaccine; Human papillomavirus (HPV); Oncogenic virus; Prevalence

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; EDUCATIONAL STATUS; FEMALE; HUMAN; INFECTION RISK; INTERVIEW; LIFESTYLE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SOCIOECONOMICS; VACCINATION; CLASSIFICATION; COMPARATIVE STUDY; DEMOGRAPHY; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; VAGINA; VIROLOGY; YOUNG ADULT;

ADULT; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; DNA, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; PREVALENCE; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; VAGINA; YOUNG ADULT;

EID: 84953876429     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1066948     Document Type: Article

References (32)

1. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660-4; PMID:25299412; http://dx.doi. org/10.1097/OLQ.0000000000000193
2. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009;10(4):321-2, PMID:19350698; http://dx.doi.org/10.1016/S1470- 2045(09)70096-8
3. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11 (11):1048-56, PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
4. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7
5. Group FIS. Quadrivalent vaccine against human papil-lomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-27, PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
6. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high- grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369 (9574):1693-1702, PMID:17512854; http://dx.doi.org/10.1016/S0140-6736(07)60777-6
7. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341:c3493, PMID:20647284; http://dx.doi.org/10.1136/bmj.c5128
8. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576-85, PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
9. Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31 (1):109-13; PMID:23137842; http://dx.doi.org/10.1016/j.vaccine.2012.10.092
10. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):24; PMID:17380109
11. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28(30):4731-7; PMID:20188681; http://dx.doi.org/10.1016/j.vaccine.2010.02.019
12. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15(5):565-80, PMID:25744474
13. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802, PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
14. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papilla-mavirus (HPV) prevalence among young women fol- lowing HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208(3):385-93; PMID:23785124; http://dx.doi.org/10.1093/infdis/jit192
15. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, et al. Effect of human papillomavi- rus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-53, PMID:17699008; http://dx.doi.org/10.1001/jama.298.7.743
16. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-9; PMID:17327523; http://dx.doi.org/10.1001/jama.297.8.813
17. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006; 24 Suppl 3:S3/106-113; PMID:16949996
18. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity Human Vaccines & Immunotherapeutics and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118 (5):2135-45, PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
19. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374-86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
20. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010;8(3):260-70, PMID:20833377; http://dx.doi.org/10.1016/j.chom.2010.08.003
21. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol. 2011;85(24):13253-9, PMID:21976653; http://dx.doi.org/10.1128/JVI.06093-11
22. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcıa P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199 (7):936-44, PMID:19236277; http://dx.doi.org/10.1086/597309
23. Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, et al. Attribution of 12 high-risk human papil- lomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997-2008, PMID:25274978; http://dx.doi.org/10.1158/1055-9965.EPI-14-0410
24. Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES 3rd, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012;30(24):3572-3579; PMID:22469863; http://dx.doi.org/10.1016/j.vaccine.2012.03.051
25. Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Galaj A, Schulze K, Suryakiran P, Thomas F, Descamps D. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG. 2015;122(1):107-18; 2343, PMID:25208608; http://dx.doi.org/10.1111/1471-0528.13070
26. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465-91; PMID:25346960
27. National Health and Nutrition Examination Survey: Questionnaires, datasets, and related documentation. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm. Accessed November 20, 2014.
28. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE. Prevalence of genitalhuman papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011;204 (4):566-73; PMID:21791659; http://dx.doi.org/10.1093/infdis/jir341
29. Design and estimation for the National Health Interview Survey, 1995-2004. Vital Health Stat 2. 2000 (130):31; PMID:AMBIGUOUS
30. Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling design. Am J Public Health. 1991;81(9):1166-73; PMID:1951829; http://dx.doi.org/10.2105/AJPH.81.9.1166
31. Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol. 2010;171(5):618-23; PMID:20133516; http://dx.doi.org/10.1093/aje/kwp440
32. Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata Journal. 2013;13(3):492-509.